

# Mark Blostein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11352572/publications.pdf>

Version: 2024-02-01

44  
papers

1,534  
citations

840119

11  
h-index

454577

30  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1935  
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581.	5.1	458
2	Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. <i>JAMA Internal Medicine</i> , 2019, 179, 1469.	2.6	283
3	The epidemiology of peripheral vein infusion thrombophlebitis: a critical review. <i>American Journal of Medicine</i> , 2002, 113, 146-151.	0.6	224
4	2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. <i>Lancet Oncology</i> , The, 2022, 23, e334-e347.	5.1	138
5	Perioperative Management of Dabigatran. <i>Circulation</i> , 2015, 132, 167-173.	1.6	133
6	The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2415-2424.	1.8	62
7	Time-dependent hardening of blood clots quantitatively measured in vivo with shear-wave ultrasound imaging in a rabbit model of venous thrombosis. <i>Thrombosis Research</i> , 2014, 133, 265-271.	0.8	44
8	Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. <i>BMJ</i> , The, 2021, 373, n1205.	3.0	38
9	Designing Personalized Treatment: An Application to Anticoagulation Therapy. <i>Production and Operations Management</i> , 2016, 25, 902-918.	2.1	22
10	Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. <i>Clinical Cardiology</i> , 2018, 41, 576-585.	0.7	19
11	Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial. <i>Lancet Haematology</i> , the, 2020, 7, e640-e648.	2.2	16
12	A multicenter prospective study of risk factors and treatment of unusual site thrombosis. <i>Thrombosis Research</i> , 2016, 144, 100-105.	0.8	12
13	Characterization of an Ideal Amphipathic Peptide as a Potential Hemostatic Agent.. <i>Blood</i> , 2006, 108, 1618-1618.	0.6	10
14	Muscle Mass and Direct Oral Anticoagulant Activity in Older Adults With Atrial Fibrillation. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1012-1018.	1.3	9
15	A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. <i>Pilot and Feasibility Studies</i> , 2020, 6, 52.	0.5	8
16	Thrombotic Complications in a Canadian Population of Critically Ill Patients with COVID-19. <i>Blood</i> , 2020, 136, 41-42.	0.6	8
17	Double Blind Randomized Control Trial of Postoperative Low Molecular Weight Heparin Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2). <i>Blood</i> , 2018, 132, 424-424.	0.6	7
18	Cost-effectiveness of eltrombopag versus intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. <i>Blood Advances</i> , 2021, , .	2.5	7

#	ARTICLE	IF	CITATIONS
19	Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: A Perioperative Management Plan for Patients with Atrial Fibrillation Who Are Receiving a Direct Oral Anticoagulant. <i>Blood</i> , 2018, 132, LBA-5-LBA-5.	0.6	6
20	Natural Killer Cells Induce the Formation of Neutrophil Extracellular Traps (NETs) in Venous Thrombosis. <i>Blood</i> , 2016, 128, 1424-1424.	0.6	6
21	Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopenia (The Tj ETQq1 1 0.784314 rgBT /Over 1.8	1.8	4
22	Performance of two clinical scales to assess quality of life in patients with post-thrombotic syndrome. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021, 9, 1257-1265.e2.	0.9	4
23	Involvement of Lipid Rafts and Caveolae in gas6-Axl Signaling in Endothelial Cells. <i>Blood</i> , 2011, 118, 2211-2211.	0.6	4
24	Thrombophilia in short peripheral catheter thrombophlebitis. <i>Thrombosis Research</i> , 2007, 119, 587-592.	0.8	3
25	Increasing Dietary Vitamin K Intake Stabilizes Anticoagulation Therapy in Warfarin-Treated Patients with a History of Instability: A 24-week Randomized Controlled Trial (OR36-04-19). <i>Current Developments in Nutrition</i> , 2019, 3, nzz035.OR36-04-19.	0.1	2
26	Development of an INR for rivaroxaban monitoring using plasma samples from patients. <i>Thrombosis Research</i> , 2020, 187, 122-124.	0.8	2
27	Post-Thrombotic Syndrome, Functional Disability and Quality of Life after Upper Extremity Deep Venous Thrombosis in Adults.. <i>Blood</i> , 2004, 104, 3514-3514.	0.6	2
28	Efficacy of Dabigatran Etexilate in a Murine Model of Cancer Associated Thrombosis. <i>Blood</i> , 2016, 128, 4991-4991.	0.6	1
29	Association Between Patient Knowledge of Anticoagulation, INR Control, and Warfarin-Related Adverse Events. <i>Journal of Pharmacy Technology</i> , 2016, 32, 150-159.	0.5	0
30	Is Thrombophilia a Risk Factor for Peripheral Vein Infusion Thrombophlebitis?.. <i>Blood</i> , 2004, 104, 4047-4047.	0.6	0
31	GAS-6 Rescues Endothelial Cells from Apoptosis through FOXO1 Inactivation.. <i>Blood</i> , 2005, 106, 3686-3686.	0.6	0
32	The Effect of Dalteparin on Coagulation Activation during Pregnancy in Women with Thrombophilia: A Randomised Trial.. <i>Blood</i> , 2006, 108, 874-874.	0.6	0
33	Use of Amphipathic Helical Peptides as An Anticoagulant. <i>Blood</i> , 2008, 112, 4100-4100.	0.6	0
34	The Role of gas6 in Venous Thrombosis In Vivo.. <i>Blood</i> , 2009, 114, 3057-3057.	0.6	0
35	In Vivo Monitoring of Venous Thrombosis in Mice.. <i>Blood</i> , 2009, 114, 5061-5061.	0.6	0
36	Report of a Case of Heyde's Syndrome Diagnosed by Abnormal Closure Times Despite Normal Von Willebrand's Activity. <i>Blood</i> , 2010, 116, 1403-1403.	0.6	0

#	ARTICLE	IF	CITATIONS
37	the Efficacy and Safety of Prothrombin Complex Concentrate In Patients Requiring Urgent Reversal of Warfarin, A Retrospective Canadian Experience. Blood, 2010, 116, 3344-3344.	0.6	0
38	Ideal Amphipathic Peptides Coupled to Nanofibrous Microspheres Reduce Hemorrhage In Vivo. Blood, 2010, 116, 2204-2204.	0.6	0
39	In Vivo Monitoring of Venous Thrombosis In Mice Using Ultrasonography. Blood, 2010, 116, 4214-4214.	0.6	0
40	Patterns of Management and Adherence to Venous Thromboembolism (VTE) Treatment Guidelines In a National Prospective Cohort Study of VTE Management In the Canadian Outpatient Setting: Recovery Study. Blood, 2010, 116, 565-565.	0.6	0
41	A Tertiary Care University Hospital Thrombosis Consultation Service: Patient Volume and Characteristics, Requesting Service and Reason for Consult. Blood, 2011, 118, 4751-4751.	0.6	0
42	ENDOTHELIAL GAS6 Contributes to Thrombogenesis and Promotes TISSUE FACTOR Upregulation DURING Vessel Injury. Blood, 2011, 118, 702-702.	0.6	0
43	Toll-Like Receptor 3 Activation Is Involved in Venous Thrombosis Development,. Blood, 2011, 118, 3277-3277.	0.6	0
44	Perioperative Eptrombopag or Intravenous Immune Globulin for Patients with Immune Thrombocytopenia: A Multicenter Randomized Trial. Blood, 2019, 134, 896-896.	0.6	0